托奇利珠单抗治疗严重急性呼吸系统综合征冠状病毒2型患者后的临床和放射学改善

Q4 Medicine

Clinical Pulmonary Medicine Pub Date : 2020-09-01 DOI:10.1097/CPM.0000000000000375

F. Barkas, Angelos Liontos, E. Svarna, A. Tsili, M. Christaki, I. Rapti, M. Argyropoulou, H. Milionis

{"title":"托奇利珠单抗治疗严重急性呼吸系统综合征冠状病毒2型患者后的临床和放射学改善","authors":"F. Barkas, Angelos Liontos, E. Svarna, A. Tsili, M. Christaki, I. Rapti, M. Argyropoulou, H. Milionis","doi":"10.1097/CPM.0000000000000375","DOIUrl":null,"url":null,"abstract":"Cytokine release syndrome and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 (COVID-19) and tocilizumab has shown efficacy in this setting We report on 2 severely ill patients with COVID-19 treated with tocilizumab within 7 to 10 days of onset of symptoms Tocilizumab markedly improved their clinical condition and was associated with regression of abnormalities on chest computed tomography within 1 week of tocilizumab administration © 2020 Wolters Kluwer Health, Inc All rights reserved","PeriodicalId":10393,"journal":{"name":"Clinical Pulmonary Medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2\",\"authors\":\"F. Barkas, Angelos Liontos, E. Svarna, A. Tsili, M. Christaki, I. Rapti, M. Argyropoulou, H. Milionis\",\"doi\":\"10.1097/CPM.0000000000000375\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cytokine release syndrome and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 (COVID-19) and tocilizumab has shown efficacy in this setting We report on 2 severely ill patients with COVID-19 treated with tocilizumab within 7 to 10 days of onset of symptoms Tocilizumab markedly improved their clinical condition and was associated with regression of abnormalities on chest computed tomography within 1 week of tocilizumab administration © 2020 Wolters Kluwer Health, Inc All rights reserved\",\"PeriodicalId\":10393,\"journal\":{\"name\":\"Clinical Pulmonary Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pulmonary Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/CPM.0000000000000375\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pulmonary Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/CPM.0000000000000375","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Clinical and Radiologic Improvement Following Tocilizumab Administration in Patients With SARS-CoV-2

Cytokine release syndrome and acute respiratory distress syndrome are the major complications of coronavirus disease 2019 (COVID-19) and tocilizumab has shown efficacy in this setting We report on 2 severely ill patients with COVID-19 treated with tocilizumab within 7 to 10 days of onset of symptoms Tocilizumab markedly improved their clinical condition and was associated with regression of abnormalities on chest computed tomography within 1 week of tocilizumab administration © 2020 Wolters Kluwer Health, Inc All rights reserved

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Pulmonary Medicine Medicine-Critical Care and Intensive Care Medicine

自引率

0.00%

发文量

期刊介绍： Clinical Pulmonary Medicine provides a forum for the discussion of important new knowledge in the field of pulmonary medicine that is of interest and relevance to the practitioner. This goal is achieved through mini-reviews on focused sub-specialty topics in areas covered within the journal. These areas include: Obstructive Airways Disease; Respiratory Infections; Interstitial, Inflammatory, and Occupational Diseases; Clinical Practice Management; Critical Care/Respiratory Care; Colleagues in Respiratory Medicine; and Topics in Respiratory Medicine.